Affiliation:
1. Key Laboratory of Polymer Ecomaterials Jilin Biomedical Polymers Engineering Laboratory Changchun Institute of Applied Chemistry Chinese Academy of Sciences Changchun 130022 P. R. China
2. School of Applied Chemistry and Engineering University of Science and Technology of China Hefei 230026 P. R. China
Abstract
AbstractDrug resistance significantly hampers the clinical application of existing platinum‐based anticancer drugs. New platinum medications that possess distinct mechanisms of action are highly desired for the treatment of Pt‐resistant cancers. Herein, a nanoscale trans‐platinum(II)‐based supramolecular coordination self‐assembly (Pt–TCPP–BA) is prepared via using trans‐[PtCl2(pyridine)(NH3)] (transpyroplatin), tetracarboxylporphyrin (TCPP), and benzoic acid (BA) as building blocks to combat drug resistance in platinum‐based chemotherapy. Mechanistic studies indicate that Pt–TCPP–BA shows a hydrogen‐peroxide‐responsive dissociation behavior along with the generation of bioactive trans‐Pt(II) and TCPP–Pt species. Different from cisplatin, these degradation products interact with DNA via interstrand cross‐links and small groove binding, and induce significant upregulation of cell‐death‐related proteins such as p53, cleaved caspase 3, p21, and phosphorylated H2A histone family member X in cisplatin‐resistant cancer cells. As a result, Pt–TCPP–BA exhibits potent killing effects against Pt‐resistant tumors both in vitro and in vivo. Overall, this work not only provides a new platinum drug for combating drug‐resistant cancer but also offers a new paradigm for the development of platinum‐based supramolecular anticancer drugs.
Funder
National Natural Science Foundation of China
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献